 |
|
CLINICIAN'S CORNER
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
Marinos C. Dalakas, MD
JAMA. 2004;291:2367-2375.
Context Intravenous immunoglobulin (IVIG) enhances immune homeostasis by modulating expression and function of Fc receptors, interfering with activation of complement and production of cytokines, providing anti-idiotypic antibodies, and affecting the activation and effector functions of T and B cells. These mechanisms may explain the effectiveness of IVIG in autoimmune neuromuscular disorders.
Objective To systematically review the current status of the treatment of autoimmune neuromuscular diseases with IVIG, with emphasis on controlled trials.
Data Sources Peer-reviewed publications identified through MEDLINE (1966-2003), EMBASE (1974-2003), and references from bibliographies of pertinent articles. Each autoimmune neuromuscular disease term was searched in combination with the term intravenous immunoglobulin.
Study Selection and Data Extraction Criteria for selection of studies included controlled study design, English language, and clinical pertinence. Data quality was based on venue of publication and relevance to clinical care.
Data Synthesis Outcomes of controlled trials indicate that IVIG at a total dose of 2 g/kg is effective as first-line therapy in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy and as second-line therapy in stiff-person syndrome, dermatomyositis, myasthenia gravis, and Lambert-Eaton myasthenic syndrome. In other controlled studies, IVIG produced a modest, variable, and transient but not statistically significant benefit in patients with inclusion body myositis and paraproteinemic anti–myelin-associated glycoprotein antibody demyelinating polyneuropathy. Intravenous immunoglobulin is not effective in patients with multiple sclerosis who have established weakness or optic neuritis. In myasthenia gravis, it should be reserved for difficult cases or before thymectomy in lieu of plasma exchange.
Conclusion Intravenous immunoglobulin is effective in many autoimmune neurologic diseases, but its spectrum of efficacy, especially as first-line therapy, and the appropriate dose for long-term maintenance therapy are not fully established. Further controlled studies of IVIG, combined with a dose-finding effect, pharmacoeconomics, and quality-of-life assessments, are warranted to improve the evidence base for clinical practice.
Author Affiliations: Neuromuscular Diseases Section, National Institutes of Health, National Institute of Neurological Disorders and Stroke, Bethesda, Md.
RELATED LETTER
Intravenous Immunoglobulin and Quality of Life
Luca Padua, Irene Aprile, Pietro Caliandro, Costanza Pazzaglia, and Pietro Tonali
JAMA. 2004;292(12):1429.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
HIGH-DOSE, RAPID-INFUSION IVIG IN POSTVACCINATION ACUTE DISSEMINATED ENCEPHALOMYELITIS
Fu and Montgomery
Neurology 2008;71:294-295.
FULL TEXT
Improvement of Intravenous Immunoglobulin Therapy for Bullous Pemphigoid by Adding Immunosuppressive Agents: Marked Improvement in Depletion of Circulating Autoantibodies
Czernik and Bystryn
Arch Dermatol 2008;144:658-661.
ABSTRACT
| FULL TEXT
Safety of Intravenous Immunoglobulin in the Treatment of Juvenile Dermatomyositis: Adverse Reactions Are Associated With Immunoglobulin A Content
Manlhiot et al.
Pediatrics 2008;121:e626-e630.
ABSTRACT
| FULL TEXT
T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis
Salajegheh et al.
Neurology 2007;69:1672-1679.
ABSTRACT
| FULL TEXT
Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies
Helmers et al.
Ann Rheum Dis 2007;66:1276-1283.
ABSTRACT
| FULL TEXT
Immunotherapy for Guillain-Barre syndrome: a systematic review
Hughes et al.
Brain 2007;130:2245-2257.
ABSTRACT
| FULL TEXT
Sialylated therapeutic IgG: a sweet remedy for inflammatory diseases?
Dimitrov et al.
Nephrol Dial Transplant 2007;22:1301-1304.
FULL TEXT
Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders
Gurcan and Ahmed
The Annals of Pharmacotherapy 2007;41:812-823.
ABSTRACT
| FULL TEXT
Neurological involvement in patients with rheumatic disease
Sofat et al.
QJM 2006;99:69-79.
ABSTRACT
| FULL TEXT
Myocardial Infarction Associated with Intravenous Immune Globulin
Stenton et al.
The Annals of Pharmacotherapy 2005;39:2114-2118.
ABSTRACT
| FULL TEXT
Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes
Raju and Dalakas
Brain 2005;128:1887-1896.
ABSTRACT
| FULL TEXT
Comparative Analysis of Antigen Specificities in the Monomeric and Dimeric Fractions of Intravenous Immunoglobulin
MIESCHER et al.
Ann. N. Y. Acad. Sci. 2005;1051:582-590.
ABSTRACT
| FULL TEXT
Inhibiting leukocyte recruitment to the brain by IVIg: is it relevant to the treatment of demyelinating CNS disorders?
Dalakas
Brain 2004;127:2569-2571.
FULL TEXT
Intravenous Immunoglobulin and Quality of Life
Padua et al.
JAMA 2004;292:1429-1429.
FULL TEXT
Intravenous Immunoglobulin and Quality of Life--Reply
Dalakas
JAMA 2004;292:1429-1430.
FULL TEXT
Other articles noted
Evid. Based Med. 2004;9:e5-e5.
FULL TEXT
|
